Karyopharm Therapeutics (NASDAQ:KPTI) Issues Earnings Results

Karyopharm Therapeutics (NASDAQ:KPTI) posted its quarterly earnings data on Tuesday. The company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.01, Zacks reports. The company had revenue of $38.78 million for the quarter, compared to analyst estimates of $37.86 million. During the same period in the prior year, the company earned ($0.30) EPS. Karyopharm Therapeutics updated its FY 2024 guidance to EPS.

Karyopharm Therapeutics Stock Performance

KPTI remained flat at $0.88 during trading on Thursday. The company had a trading volume of 1,306,431 shares, compared to its average volume of 1,269,642. The firm has a market capitalization of $109.99 million, a PE ratio of -0.76 and a beta of 0.16. Karyopharm Therapeutics has a 52-week low of $0.62 and a 52-week high of $1.95. The business’s 50 day moving average price is $0.81 and its 200 day moving average price is $0.91.

Analyst Ratings Changes

KPTI has been the topic of a number of recent analyst reports. StockNews.com downgraded shares of Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday. Robert W. Baird reduced their target price on Karyopharm Therapeutics from $8.00 to $5.00 and set an “outperform” rating on the stock in a report on Wednesday, August 7th. HC Wainwright restated a “buy” rating and set a $7.00 price target on shares of Karyopharm Therapeutics in a research note on Friday, November 1st. Piper Sandler raised their price target on shares of Karyopharm Therapeutics from $4.00 to $5.00 and gave the company an “overweight” rating in a report on Wednesday. Finally, Royal Bank of Canada restated an “outperform” rating and set a $3.00 target price on shares of Karyopharm Therapeutics in a report on Wednesday, August 7th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat, Karyopharm Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $5.00.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).